The Maine Medical Center Institutional Biosafety Committee (IBC) is a standing committee that has oversight of recombinant DNA (rDNA) research. All NIH funded rDNA research must be reviewed by the IBC per NIH Guidelines for Research Involving Recombinant DNA Molecules.

All activities proposed to involve the use of recombinant DNA must first seek approval from the Institutional Biosafety Committee. The IBC reviews and approves research to ensure safe practices, procedures, as well as handling and use of biohazardous materials for research at MaineHealth Institute for Research.

IBC meetings are held as needed. The most likely date of an IBC meeting is directly before or after a scheduled Institutional Animal Care and Use Committee (IACUC) meeting (see IACUC 2024 meeting schedule).

Forms:

*If a PDF does not show content, your browser may not have the latest version of Adobe Reader. Right-click on the document and save to your desktop to view.

IBC Initial Review Form
IBC Annual Review Form
IBC Closure Notice Form

Helpful Links:

BMBL – Biosafety in Microbiology & Biomedical Laboratories
NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules

Questions? Contact:

Calvin Vary, PhD
IBC Chairmain
Calvin.Vary@mainehealth.org

MaineHealth Office of Research Ethics & Compliance

1 Riverfront Plaza
Westbrook, Maine 04092
mmc_irb@mainehealth.org
207.661.4474